A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

PHASE2CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

May 30, 2023

Study Completion Date

November 13, 2023

Conditions
Chronic Obstructive Pulmonary Disease (COPD)Chronic Bronchitis
Interventions
DRUG

Tozorakimab

Participants will receive SC injection of tozorakimab as stated in arm description.

OTHER

Placebo

Participants will receive SC injection of placebo as stated in arm description.

Trial Locations (90)

110

Research Site, Taipei

114

Research Site, Taipei

333

Research Site, Taoyuan

807

Research Site, Kaohsiung City

1033

Research Site, Budapest

2100

Research Site, Gödöllő

2113

Research Site, Johannesburg

2400

Research Site, København NV

2650

Research Site, Hvidovre

2660

Research Site, Balassagyarmat

3110

Research Site, Tauranga

3780

Research Site, Edelény

4001

Research Site, Durban

4032

Research Site, Debrecen

4080

Research Site, Hajdúnánás

4101

Research Site, South Brisbane

4121

Research Site, Tarragindi

4700

Research Site, Næstved

5000

Research Site, Odense C

6009

Research Site, Nedlands

6021

Research Site, Wellington

6163

Research Site, Spearwood

7530

Research Site, Tygervalley

7635

Research Site, Pécs

7700

Research Site, Cape Town

8013

Research Site, Christchurch

9000

Research Site, Aalborg

10717

Research Site, Berlin

13187

Research Site, Berlin

15213

Research Site, Pittsburgh

19713

Research Site, Newark

21162

Research Site, White Marsh

28007

Research Site, Madrid

28562

Research Site, New Bern

29010

Research Site, Málaga

29303

Research Site, Spartanburg

29406

Research Site, North Charleston

32174

Research Site, Ormond Beach

32789

Research Site, Winter Park

34746

Research Site, Kissimmee

35037

Research Site, Marburg

35660

Research Site, Sheffield

37007

Research Site, Salamanca

39010

Research Site, Santander

41017

Research Site, Lakeside Park

43215

Research Site, Columbus

46600

Research Site, Alzira

48197

Research Site, Ann Arbor

50009

Research Site, Zaragoza

55128

Research Site, Mainz

64283

Research Site, Darmstadt

73120

Research Site, Oklahoma City

77900

Research Site, Olomouc

78006

Research Site, Boerne

83301

Research Site, Kaohsiung City

91031

Research Site, Jerusalem

91120

Research Site, Jerusalem

92663

Research Site, Newport Beach

96049

Research Site, Bamberg

7661041

Research Site, Rehovot

7830604

Research Site, Ashkelon

A1B 3V6

Research Site, St. John's

L1S 2J5

Research Site, Ajax

G1G 3Y8

Research Site, Québec

G2J 0C4

Research Site, Québec

J1L 0H8

Research Site, Sherbrooke

G8T 7A1

Research Site, Trois-Rivières

625 00

Research Site, Brno

397 01

Research Site, Písek

140 46

Research Site, Prague

337 22

Research Site, Rokycany

D-30173

Research Site, Hanover

04107

Research Site, Leipzig

5623EJ

Research Site, Eindhoven

3083 AN

Research Site, Rotterdam

7207 AE

Research Site, Zutphen

0626

Research Site, Auckland

15-044

Research Site, Bialystok

85-079

Research Site, Bydgoszcz

40-648

Research Site, Katowice

31-501

Research Site, Krakow

60-693

Research Site, Poznan

33-100

Research Site, Tarnów

54-239

Research Site, Wroclaw

06800

Research Site, Mérida

BD9 6RJ

Research Site, Bradford

BS105NB

Research Site, Bristol

EH16 4SA

Research Site, Edinburgh

EC1A 7BE

Research Site, London

NE7 7DN

Research Site, Newcastle upon Tyne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY